Deli Hong
Overview
Explore the profile of Deli Hong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
917
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Mahadevan N, Duplaquet L, Hong D, Durmaz Y, Jones K, et al.
Cell Rep Med
. 2023 Nov;
4(11):101282.
PMID: 37992688
Despite small cell lung cancers (SCLCs) having a high mutational burden, programmed death-ligand 1 (PD-L1) immunotherapy only modestly increases survival. A subset of SCLCs that lose their ASCL1 neuroendocrine phenotype...
2.
Duplaquet L, Li Y, Booker M, Xie Y, Olsen S, Patel R, et al.
Nat Cell Biol
. 2023 Aug;
25(9):1346-1358.
PMID: 37591951
Small cell lung cancer (SCLC) exists broadly in four molecular subtypes: ASCL1, NEUROD1, POU2F3 and Inflammatory. Initially, SCLC subtypes were thought to be mutually exclusive, but recent evidence shows intra-tumoural...
3.
Hong D, Knelson E, Li Y, Durmaz Y, Gao W, Walton E, et al.
Cancer Res
. 2021 Nov;
82(2):248-263.
PMID: 34810201
Neuroendocrine to nonneuroendocrine plasticity supports small cell lung cancer (SCLC) tumorigenesis and promotes immunogenicity. Approximately 20% to 25% of SCLCs harbor loss-of-function (LOF) mutations. Previous studies demonstrated that NOTCH functions...
4.
Mahadevan N, Knelson E, Wolff J, Vajdi A, Saigi M, Campisi M, et al.
Cancer Discov
. 2021 Mar;
11(8):1952-1969.
PMID: 33707236
Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity, which could influence its immunobiology. Here we...
5.
Fritz A, Hong D, Boyd J, Kost J, Finstaad K, Fitzgerald M, et al.
J Cell Physiol
. 2020 Mar;
235(10):7261-7272.
PMID: 32180230
Breast cancer stem cells (BCSCs) are competent to initiate tumor formation and growth and refractory to conventional therapies. Consequently BCSCs are implicated in tumor recurrence. Many signaling cascades associated with...
6.
Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long M, et al.
Nat Commun
. 2020 Feb;
11(1):1095.
PMID: 32094369
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
7.
Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long M, et al.
Nat Commun
. 2020 Jan;
11(1):338.
PMID: 31953400
Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant prostate cancer (CRPC) and NEPC, but its specific role...
8.
Farina N, Scalia S, Adams C, Hong D, Fritz A, Messier T, et al.
J Cell Physiol
. 2020 Jan;
235(6):5318-5327.
PMID: 31919859
Despite recent advances in targeted therapies, the molecular mechanisms driving breast cancer initiation, progression, and metastasis are minimally understood. Growing evidence indicate that transfer RNA (tRNA)-derived small RNAs (tsRNA) contribute...
9.
Rajabi H, Hata T, Li W, Long M, Hu Q, Liu S, et al.
Oncogene
. 2019 Oct;
38(47):7278.
PMID: 31576011
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
10.
Hata T, Rajabi H, Takahashi H, Yasumizu Y, Li W, Jin C, et al.
Cancer Res
. 2019 Sep;
79(22):5711-5722.
PMID: 31519689
The NuRD chromatin remodeling and deacetylation complex, which includes MTA1, MBD3, CHD4, and HDAC1 among other components, is of importance for development and cancer progression. The oncogenic mucin 1 (MUC1)...